Thyroid dysfunction and dyslipidemia in chronic kidney disease patients by unknown
RESEARCH ARTICLE Open Access
Thyroid dysfunction and dyslipidemia in
chronic kidney disease patients
Saroj Khatiwada1*, Rajendra KC2, Sharad Gautam2, Madhab Lamsal2 and Nirmal Baral2
Abstract
Background: Chronic kidney disease (CKD) is becoming a serious health problem; the number of people with
impaired renal function is rapidly rising. Progression of CKD is associated with having a number of complications,
including thyroid dysfunction, dyslipidemia and cardiovascular diseases. This study was conducted to investigate
thyroid function and lipid profile in CKD patients.
Methods: A cross-sectional study was conducted among 360 chronic kidney disease patients at B P Koirala Institute
of Health Sciences, Dharan, Nepal. Demographic features (age and sex) and medical history of diabetes mellitus,
hypertension and cardiovascular diseases of each patient were noted, and blood samples (5 ml) were analyzed for
serum urea, creatinine, glucose, free triiodothyronine (T3), free thyroxine (T4), thyroid stimulating hormone (TSH), total
cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglyceride.
Results: Thyroid dysfunction was found in 38.6 % CKD patients, the most common being subclinical hypothyroidism
(27.2 %), followed by overt hypothyroidism (8.1 %) and subclinical hyperthyroidism (3.3 %). Hypercholesterolemia,
low HDL cholesterol, undesirable LDL cholesterol and hypertriglyceridemia were observed in 34.4, 34.1, 35 and 36.6 %
patients respectively. Stage 4 and 5 CKD patients had significantly higher risk of having thyroid dysfunction as compared
to stage 3 patients. Significant risk factors for cardiovascular disease in CKD patients included presence of diabetes
mellitus, hypercholesterolemia, undesirable LDL cholesterol and being in stage 4 and 5 (as compared to stage 3).
Conclusions: Thyroid dysfunction, hypercholesterolemia, low HDL cholesterol, undesirable LDL cholesterol and
hypertriglyceridemia are common in CKD patients. Progression of CKD is accompanied by rise in hypothyroidism and
cardiovascular disease.
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Background
Chronic kidney disease (CKD) is becoming a serious
health problem; the number of people with impaired
renal function is rapidly rising, especially in industrial-
ized countries [1]. Recent reports, however, suggest an
abrupt rise in CKD in developing countries from Asia
due to increase in concomitant diseases such as type 2
diabetes, hypertension and cardiovascular diseases
(CVDs) [2]. Associated with rise in CKD numbers is the
extensive increase in the health cost for management of
CKD especially of 5th stage [3].
Reports suggest that progression of CKD is associated
with having a number of complications, including thy-
roid dysfunction, dyslipidemia and CVD [4]. The kidney
normally plays an important role in the metabolism,
degradation and excretion of thyroid hormones. CKD
affects the hypothalamus pituitary thyroid axis. CKD
affects thyroid function in many ways, including low
circulating thyroid hormone levels, altered peripheral
hormone metabolism, insufficient binding to carrier pro-
teins, reduced tissue thyroid hormone content and
altered iodine storage in the thyroid gland. Thus, in
CKD, thyroid hormone metabolism is impaired [5]. CKD
is associated with a higher prevalence of primary
hypothyroidism, both overt and subclinical, but not with
hyperthyroidism. Prevalence of primary hypothyroidism,
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mainly in the subclinical form, increases as glomerular
filtration rate (GFR) decreases [6].
Dyslipidemia has been established as a well-known
traditional risk factor for CVD in CKD and large-scale
observational studies have shown that total and low-
density lipoprotein (LDL) cholesterol are the most
important independent predictors of cardiovascular
morbidity and mortality [7]. Several factors contribute to
the development dyslipidemia associated with chronic
renal impairment. Patients with CKD have a reduction
in the activity of lipoprotein lipase and hepatic triglycer-
ide lipase. This interferes with uptake of triglyceride rich,
apolipoprotein B containing lipoproteins by the liver and
in peripheral tissue, yielding increased circulation of
these atherogenic lipoproteins [4]. Progression of CKD is
accompanied by the development of specific alterations
of the lipoprotein metabolism [8]. Reports show that
mortality due to CVD was 10–30 times higher in dialysis
patients than in the general population [9].
There is growing evidence that abnormalities in lipid
metabolism may contribute to renal disease progression
[10]. Thyroid dysfunction and dyslipidemia in CKD may
further increase CVD risk leading to increased morbidity
and mortality. Hence, early diagnosis of thyroid and lipid
disorders by regular screening, and treatment of such
disorders in CKD patients may be highly beneficial to
slow the progression of CKD, in addition to the preven-
tion of CVD risk [4, 6]. A study in eastern Nepal,
reported CKD in 10.6 % of general community with
age and diabetes mellitus being the significant predic-
tors for CKD [11]. Another small study reported dys-
lipidemia to be very common in Nepalese CKD
patients [12]. In view of the decreased thyroid func-
tion and dyslipidemia in CKD patients, and the lack
of data for thyroid function and dyslipidemia in
Nepalese population with CKD, we undertook the
present study in the population with CKD.
Methods
A cross-sectional study was conducted among CKD
patients attending biochemistry laboratory of B P Koirala
Institute of Health Sciences, Dharan, Nepal from Febru-
ary 2012 to March 2014 to investigate thyroid function
and lipid profile in CKD stage 3–5. A total of 360 newly
diagnosed and known CKD cases (stage 3 to stage 5)
were included in the study. CKD was defined on the
basis of National Kidney Foundation guidelines of hav-
ing an estimated glomerular filtration rate (eGFR) <
60 ml/min/1.732 m2 for more than 3 months. The
Modification of Diet in Renal Disease study (MDRD)
equation was used to calculate eGFR [13]. Patients with
known thyroid disorders, on medications affecting thy-
roid function and on lipid lowering agents were ex-
cluded from the study. The study protocol was approved
by the Institutional Review Board of the B P Koirala
Institute of Health Sciences, Dharan and consents were
obtained from each patient.
Demographic features (age and sex) and medical his-
tory of diabetes mellitus, hypertension and CVD of each
patient were noted, and blood samples (5 ml) were col-
lected. CVD was defined as a history of coronary heart
disease, congestive heart failure, peripheral arterial dis-
ease or stroke. Blood was analyzed for serum urea,
creatinine, glucose, total cholesterol, high density lipo-
protein (HDL) cholesterol, low density lipoprotein (LDL)
cholesterol, triglyceride, triiodothyronine (T3), thyroxine
(T4) and thyroid stimulating hormone (TSH). Serum
urea level and blood glucose were estimated using
enzymatic methods and creatinine by Jaffe method.
Serum free T3, free T4 and TSH were measured by
using fluorescent immunoassay (VIDAS, biomeriux SA,
France). Similarly, total cholesterol, HDL cholesterol,
LDL cholesterol and triglycerides were measured using
kits from AGAPPE diagnostics by Biolyzer 100.
Thyroid dysfunction was considered if patients thyroid
hormones fall outside the reference range; free T3 (4.0–
8.3 pmol/L), free T4 (9.0–20.0 pmol/L) and TSH (0.25–5
mIU/L). Euthyroid was considered if thyroid hormone
levels fall within reference range. Overt hypothyroidism
was defined as TSH > 5 mIU/L and free T3 < 4.0 pmol/L
and free T4 < 9.0 pmol/L. Subclinical hypothyroidism
was considered if TSH > 5 mIU/L and free T3 and free
T4 within reference range. Subclinical hyperthyroidism
was defined as TSH < 0.25 mIU/L and free T3 and free
T4 within reference range. The data generated from
study was entered into MS excel and analyzed using
SPSS version 11.0. The data were expressed as mean ±
SD (for normal distribution) and median (for non-
normal distribution) for continuous variables and as per-
centage (number) for categorical variables. One way
ANOVA and Kruskal Wallis test were applied for con-
tinuous variables and chi square test for categorical vari-
ables at 95 % confidence interval. Odds ratio with 95 %
confidence interval (CI) was calculated to assess differ-
ent risk factors for thyroid dysfunction and CVD in
CKD patients.
Results
The study population comprised 360 CKD patients with
53.8 % males and 46.1 % females. The mean age of study
population was 44.1 ± 16.4 years. Stage 3, stage 4 and stage
5 CKD patients were 40 % (n = 144), 43.3 % (n = 156) and
16.6 % (n = 60) respectively. Various clinical and biochem-
ical parameters of study population according to CKD
stages are shown in Table 1. Diabetes and CVD prevalence
in CKD showed significantly increasing trend from stage 3
to 5. Blood urea, creatinine and TSH level increased
significantly across CKD stages 3–5. Prevalence of
Khatiwada et al. BMC Endocrine Disorders  (2015) 15:65 Page 2 of 7
diabetes mellitus, hypertension and CVD was; 45.8, 63.8
and 29.8 % in stage 3; 40.3, 72.4 and 51.9 % in stage 4; and
60, 80 and 75 % in stage 5 CKD patients respectively.
Thyroid function status and dyslipidemia according to
CKD stages is shown in Table 2. Thyroid dysfunction
was found in 38.6 % CKD patients, the most common
thyroid dysfunction being subclinical hypothyroidism
(27.2 %). Subclinical hypothyroidism got significantly
common with CKD progression. Prevalence of subclin-
ical hypothyroidism in stage 3, stage 4 and stage 5 was
15.2, 32.0 and 43.3 % respectively. Hypercholesterolemia
(total cholesterol > 200 mg/dL), low HDL (HDL
cholesterol < 40 mg/dL), undesirable LDL (LDL choles-
terol > 100 mg/dL) and hypertriglyceridemia (triglycer-
ide > 200 mg/dL) was; 38.8, 33.3, 38.8 and 34.7 % in
stage 3; 32.6, 35.8, 32.0 and 38.4 % in stage 4; and 28.3,
31.6, 33.3 and 36.6 % in stage 5 respectively.
The odds ratio of having hypercholesterolemia, low
HDL, undesirable LDL and hypertriglyceridemia in stage
4 patient was 0.76 (95 % CI: 0.47–1.22, p = 0.263), 1.12
(95 % CI: 0.69–1.8, p = 0.641), 0.74 (95 % CI: 0.46–1.19,
p = 0.216) and 1.17 (95 % CI: 0.73–1.88. p = 0.502) re-
spectively as compared to stage 3 patients. Similarly, the
odds ratio of having hypercholesterolemia, low HDL,
Table 1 Characteristics of study patients according to CKD stage
Variables All patients N = 360 Stage 3 N = 144 Stage 4 N = 156 Stage 5 N = 60 P value
Age (Years) 44.1 ± 16.4 41.9 ± 16.1 47.5 ± 15.6 40.3 ± 17.7 0.002
Sex
Male 53.8 % (194) 18.8 % (68) 25.2 % (91) 9.7 % (35) 0.117
Female 46.1 % (166) 21.1 % (76) 18.0 % (65) 6.9 % (25)
Diabetes mellitus 45.8 % (165) 18.3 % (66) 17.5 % (63) 10 % (36) 0.035
Hypertension 70.2 % (253) 25.5 % (92) 31.3 % (113) 13.3 % (48) 0.053
Cardiovascular disease 46.9 % (169) 11.9 % (43) 22.5 % (81) 12.5 % (45) <0.001
Urea (mg/dL) 106.3 ± 60.1 71.3 ± 39.5 100.7 ± 37.7 204.7 ± 39.5 <0.001
Creatinine (mg/dL) 4.0 ± 3.4 1.8 ± 0.3 3.3 ± 0.5 10.9 ± 3.2 <0.001
eGFR (ml/min per 1.73 m2) 28.2 ± 15.3 44.0 ± 8.9 22.0 ± 4.0 6.4 ± 2.6 <0.001
Free T3 (pmol/L) 4.9 ± 1.1 5.0 ± 1.1 4.9 ± 1.1 4.7 ± 0.8 0.131
Free T4 (pmol/L) 11.6 ± 3.2 11.9 ± 3.2 11.5 ± 3.3 11.0 ± 2.6 0.175
TSH (mIU/L) 3.2 (1.8, 6.8) 2.5 (1.6, 4.3) 3.3 (1.7, 7.3) 5.4 (2.3, 8.8) <0.001
Glucose (mg/dL) 117.4 ± 44.6 119.9 ± 45.6 116.7 ± 46.7 113.0 ± 36.1 0.596
Total cholesterol (mg/dL) 191.9 ± 31.7 194.2 ± 32.9 189.9 ± 31.3 191.6 ± 29.4 0.501
HDL cholesterol (mg/dL) 42.1 ± 5.9 42.0 ± 5.8 42.0 ± 6.0 42.7 ± 6.1 0.718
LDL cholesterol (mg/dL) 103.6 ± 28.1 106.1 ± 30.9 100.6 ± 25.6 105.0 ± 26.7 0.215
Triglyceride (mg/dL) 205.7 ± 73.9 205.9 ± 79.8 207.1 ± 70.4 201.6 ± 68.8 0.884
The data is presented as mean ± SD (except for TSH level which showed non-normal distribution and is expressed as median) for continuous variables and as
percentage (number) for categorical variables. P value was calculated at 95 % confidence interval among CKD stages 3–5 for different variables using one way
ANOVA and Kruskal Wallis test for continuous variables, and chi square test for categorical variables
Table 2 Thyroid dysfunction and dyslipidemia in different CKD stages
Variables All patients N = 360 Stage 3 N = 144 Stage 4 N = 156 Stage 5 N = 60 P value
Thyroid status
Euthyroidism 61.4 % (221) 29.4 % (106) 24.7 % (89) 7.2 % (26) <0.001
Subclinical hypothyroidism 27.2 % (98) 6.1 % (22) 13.9 % (50) 7.2 % (26) <0.001
Overt hypothyroidism 8.1 % (29) 2.5 % (9) 3.3 % (12) 2.2 % (8) 0.232
Subclinical hyperthyroidism 3.3 % (12) 1.9 % (7) 1.4 % (5) - 0.21
Hypercholesterolemia (Total cholesterol > 200 mg/dL) 34.4 % (124) 15.5 % (56) 14.1 % (51) 4.7 % (17) 0.292
Low HDL cholesterol (HDL cholesterol <40 mg/dL) 34.1 % (123) 13.3 % (48) 15.5 % (56) 5.2 % (19) 0.811
Undesirable LDL cholesterol (LDL cholesterol > 100 mg/dL) 35 % (126) 15.5 % (56) 13.8 % (50) 5.5 % (20) 0.443
Hypertriglyceridemia (Triglyceride > 200 mg/dL) 36.6 % (132) 13.8 % (50) 16.6 % (60) 6.1 % (22) 0.798
The data is presented as percentage (number). P value was calculated among CKD stages 3–5 for different variables using chi square test at 95 % confidence interval
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undesirable LDL and hypertriglyceridemia in stage 5
patient was 0.62 (95 % CI: 0.32–1.19, p = 0.152), 0.92
(95 % CI: 0.48–1.76, p = 0.817), 0.78 (95 % CI: 0.41–1.47,
p = 0.455) and 1.08 (95 % CI: 0.58–2.03, p = 0.791)
respectively as compared to stage 3 patients.
The odds ratio of having thyroid dysfunction and
CVD in CKD patients due to various risk factors is
shown in Table 3. There were significant odds of having
thyroid dysfunction in stage 4 and 5 as compared to
stage 3 CKD. Presence of diabetes, hypercholesterolemia
and undesirable LDL cholesterol had significant odds of
having CVD. Stage 4 and 5 patients had significant odds
of having CVD as compared to stage 3 patients. The
odds of having CVD in CKD patients with thyroid dys-
function was 1.25 (95 % CI: 0.81–1.91, p = 0.303) as
compared to euthyroids. eGFR had significant positive
correlation with free T3 (r = 0.11, p = 0.036), free T4 (r =
0.119, p = 0.024) and significant negative correlation with
TSH (r = −2.01, p < 0.001) but no correlation with
parameters of lipid profile.
Discussion
The present study identifies thyroid dysfunction and dys-
lipidemia as a common disorder in Nepalese CKD patients.
Thyroid dysfunction was found in 38.6 % CKD patients,
the most common being subclinical hypothyroidism
(27.2 %), followed by overt hypothyroidism (8.1 %) and
subclinical hyperthyroidism (3.3 %). We found higher
prevalence of thyroid dysfunction in CKD patients than
shown by other studies. A small study in hemodialysis
patients in western Nepal showed the combined preva-
lence of subclinical and clinical hypothyroidism in 26.6 %
patients [14]. Study by Lo et al. found that the prevalence
of hypothyroidism increased with lower levels of GFR (in
units of mL/min/1.73 m2), occurring in 5.4 % of subjects
with GFR greater than or equal to 90, 10.9 % with GFR
60–89, 20.4 % with GFR 45–59, 23.0 % with GFR 30–44,
and 23.1 % with GFR < 30 (p < 0.001 for trend). They
reported that 56 % of hypothyroidism cases were sub-
clinical [6]. In a study in India among end stage renal
failure (ESRD) patients, prevalence of subclinical
hypothyroidism was 24.8 % [15]. A study by Ng et al.
in peritoneal dialysis (PD) patients of Taiwan reported
that, 98 (80.3 %) were having euthyroidism; 19
(15.6 %), subclinical hypothyroidism; and 5 (4.1 %),
subclinical hyperthyroidism [16]. High rate of thyroid
dysfunction in CKD patients as observed in our study
may also be due to high prevalence of thyroid auto-
immunity in study population, excess iodine nutrition
or iodine deficiency, and the inclusion of subjects
with non thyroidal illness [17, 18].
We observed decreasing trend for free T3 and free T4
levels (though the decrease were not significant), and
increasing trend for TSH level (significant rise) across
CKD stages 3–5, which suggest that TSH level increases
with the progression of renal impairment (which is indi-
cated by a decrease in GFR). Prevalence of subclinical
hypothyroidism was much common in stage 5 (43.3 %),
than stage 4 (32.0 %) and stage 3 (15.2 %) patients,
which clearly demonstrates the parallel rise in
Table 3 Risk factors for thyroid dysfunction and cardiovascular disease in CKD
Risk factors Odds ratio (95 % CI) P value
Thyroid dysfunction Female gender 1.26 (0.82–1.92) 0.287
Age > 60 years 1.53 (0.92–2.55) 0.098
Diabetes mellitus 0.96 (0.63–1.48) 0.878
CKD stage
Stage 3 1 (reference)
Stage 4 2.1 (1.28–3.42) 0.003
Stage 5 3.64 (1.94–6.85) <0.001
Cardiovascular disease Hypertension 1.25 (0.79–1.97) 0.328
Diabetes mellitus 1.93 (1.26–2.94) 0.002
Hypercholesterolemia 4.95 (3.08–7.97) <0.001
Low HDL cholesterol 1.06 (0.68–1.64) 0.779
Undesirable LDL cholesterol 2.83 (1.8–4.43) <0.001
CKD stage
Stage 3 1 (reference)
Stage 4 2.53 (1.57–4.08) <0.001
Stage 5 7.04 (3.55–13.97) <0.001
Hypercholesterolemia, low HDL and undesirable LDL were considered if total cholesterol > 200 mg/dL, HDL cholesterol < 40 mg/dL and LDL cholesterol > 100 mg/dL
respectively. Stage 3 CKD was considered as reference for calculating odds for thyroid dysfunction and CVD in stage 4 and stage 5 CKD
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hypothyroidism with CKD progression. Our findings, are
similar to the study by Song et al. who found that there
was an increasing trend for the population of low T3 ac-
cording to the increase of a CKD stage (eGFR ≥ 90,
8.2 %; ≥60 eGFR < 90, 10.9 %; ≥30 eGFR < 60, 20.8 %;
≥15eGFR < 30, 60.6 %; eGFR < 15, 78.6 %) [19]. In the
present study, we found that stage 4 and 5 patients had
significantly high risk for thyroid dysfunction as com-
pared to stage 3 patients, which is consistent with the
findings of Lo et al., who observed increased risk for
hypothyroidism with the decrease in GFR [6]. Song et
al., also observed a positive relationship between eGFR
and serum T3 and after adjusting for age and sex, com-
pared with eGFR ≥ 60 ml/min/1.73 m2, eGFR < 60 ml/
min/1.73 m2 was associated with an increased odds of
low T3 (odds ratio 2.40) [19]. In a study in Saudi Arabia,
there was a significant decrease in the levels of serum
total T3, total T4 and total protein and albumin levels in
CKD patients when compared with the controls. There
was a significant increase in the level of TSH in the
CKD patients compared with the controls [20]. However,
a study in undialyzed CKD patients found that both T3
and T4 were significantly reduced whereas TSH remains
to be unchanged in patient group compared to controls
[21].
We found subclinical hypothyroidism (27.2 %) to be very
common in CKD patients. It has been estimated that the
prevalence of subclinical hypothyroidism ranges between 4
and 10 % in the general population and it has been well ob-
served that hypothyroidism (overt or clinical) increases the
risk for CVD. Subclinical hypothyroidism has been identi-
fied as a strong predictor of all-cause mortality in chronic
dialysis patients and as a risk factor for nephropathy and
cardiovascular events in type 2 diabetic patients [22]. In the
present study, however, we did not observed significant risk
of having CVD in CKD patients with thyroid dysfunction
especially subclinical hypothyroidism as compared to those
with normal thyroid function. A number of studies have
reported that subclinical hypothyroidism is associated with
an increased risk of coronary heart disease and there
appears to be a significant increase in a cluster of metabolic
CVD risk factors among people with subclinical
hypothyroidism [23, 24]. The reduced T3 level, the reduced
free T4 levels along with an elevated TSH raises the possi-
bility of benefit from thyroid supplementation in CKD.
However, it is still debatable about the importance and
necessity of thyroid hormone supplementation in CKD
patients and concrete evidence is not available for recom-
mending supplementation of thyroid hormones in CKD
patients [25].
In general, the prevalence of hyperlipidemia increases
as renal function declines, with the degree of hypertri-
glyceridemia and elevation of LDL cholesterol being pro-
portional to the severity of renal impairment [4]. CKD
affects lipoprotein metabolism, leading to hypercholes-
terolemia, hypertriglyceridemia and excess LDL choles-
terol [26]. In the present study, we reported dyslipidemia
in significant number of CKD patients. Hypercholester-
olemia, low HDL, undesirable LDL and hypertriglyc-
eridemia was observed in 34.4, 34.1, 35 and 36.6 %
patients respectively. Our finding are similar to the
results of a study in Kathmandu, Nepal, where hyper-
cholesterolemia, low HDL cholesterol, high LDL choles-
terol and hypertriglyceridemia was present in 33.75,
32.5, 38.03 and 35.58 % CKD patients respectively, and
CKD patients had higher odds of developing dyslipid-
emia as compared to non-CKD controls [12]. We how-
ever, did not found that stage 4 and stage 5 patients
have significant odds of developing dyslipidemia as com-
pared to stage 3 patients. Many studies have reported
rise in level of lipid parameters and dyslipidemia preva-
lence in CKD patients, which may further assist in renal
disease progression [10]. Study by Raju et al. found that
there was a significant increase of serum triglycerides
and very low density lipoprotein (VLDL) with a decrease
in serum HDL cholesterol in both non dialysis and
hemodialysis groups of CKD patients when compared
with control. But there was no alteration in serum total
cholesterol and LDL cholesterol in both groups [27].
Dyslipidemia in CKD may have significant impact,
especially for CVD risk [7]. Our finding suggest for the
significant association between the presence of cardio-
vascular disease with hypercholesterolemia and high
LDL cholesterol in CKD patients. Our study reveals that
CKD progression is strongly associated with CVD preva-
lence. Stage 4 and stage 5 patients had higher risk for
having CVD as compared to stage 3 patients. The study
however, did not find significant rise in dyslipidemia
cases during CKD progression. A large number of epide-
miologic studies have suggested the independent role of
dyslipidemia on cardiovascular morbidity and mortality
in the general population [10]. But, the role of dyslipid-
emia in the pathophysiology of atherosclerotic disease in
patients with CKD remains controversial. Some studies
have shown a positive association between cholesterol
values and the risk for cardiovascular events in CKD
individuals, whereas others failed to find any significant
correlation. Although the precise causes of this signifi-
cant deviation from what is observed in the general
population have not been established, it has been pro-
posed that the presence of phenomena such as inflam-
mation or protein energy wasting (conditions very
common in ESRD patients) may significantly confound
the relationship between the traditional risk factors for
CVD and mortality in CKD patient population [26].
Study by Chen et al. demonstrated that certain levels of
dyslipidemia were independently associated with renal
replacement therapy and rapid renal progression in CKD
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stage 3–5. Thus, assessment of lipid profile in CKD
patients may help identify high risk groups with ad-
verse renal outcomes [10]. Among, the various risk
factors for CVD we considered, only diabetes had sig-
nificant association with CVD occurrence. Diabetic
condition had also significant association with progression
of CKD. Diabetes is said to be the leading cause of CKD
in many populations and is associated with excessive
cardiovascular morbidity and mortality [28].
Thyroid disorders and CKD are independently some of
the most prominent medical conditions found in pa-
tients in many countries. Clinicians, including nephrolo-
gists, must consider the dangers of thyroid disease and
its appropriate treatment in conjunction to treating
CKD. Thyroid dysfunction causes significant changes in
kidney function and kidney diseases can be associated
with thyroid disorders. Thus, both CKD and thyroid dys-
function mutually influence each other [29]. Similarly,
dyslipidemia is the leading risk factor for CVD in CKD
patients, and CVD remains the leading cause of death in
CKD patients. Kidney Disease Outcomes Quality Initia-
tive (K/DOQI) working group has suggested that, all
adults and adolescents with CKD should be evaluated
for dyslipidemias because of high risk for CVD [30].
Our findings of present study have great clinical
significance. It suggest for the importance of regular
screening and treatment of thyroid dysfunction and dys-
lipidemia in patients with CKD, which may further help
to prevent CVD risk. This would help in better clinical
management of CKD patients and thus better quality of
life. So, we recommend for regular checkup of thyroid
function and lipid profile in CKD patients. It should be
however noted that, since the study was conducted in a
region of Nepal where conditions (nutrition status, dis-
ease status, thyroid autoimmunity status, genetic com-
ponents) of patients may be slightly different than other
parts of world, the present findings may vary somewhat
for other countries. The present study has some limita-
tions which should be noted. First, patients with non
thyroidal illness (which is typically seen in some ill
patients, including those with end-stage renal disease)
were not identified, since thyroid testing was done only
once. This may have resulted in higher rate of thyroid
dysfunction in the present study due to inclusion of
some patients with non thyroidal illness. Second, the
iodine status of the subjects was not studied, so excess
iodine nutrition or iodine deficiency in these regions
may contribute to thyroid disorders, mainly subclinical
hypothyroidism [18]. Third, we did not assess thyroid
autoimmunity status in the study population. High
prevalence of thyroidal autoimmunity is related with in-
creased thyroid dysfunction, so high rate of thyroid auto-
immunity (if present) may have contributed for high
thyroid dysfunction rate in the present study [17].
Further studies should explore potential causal mech-
anisms through which CKD may be associated with
increased TSH and reduced thyroid function, includ-
ing the possible roles of autoimmunity and iodine
excess, and the mechanism of dyslipidemia in patients
with CKD.
Conclusions
In summary, the present study finds thyroid dysfunction
to be very common in CKD patients and reveals the
significant association between CKD progression and
thyroid dysfunction. The study also finds dyslipidemia
as a common disorder in CKD. The study reveals that
CKD patients with elevated lipid parameters have
strong risk for developing CVD, so early treatment
for lipid abnormalities in CKD patients may lower the
chance of developing CVD later.
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